Technology Advances, High-Risk Research, and a Safe Way Forward.

advanced technologies high-risk research leadership nuanced regulation

Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
26 10 2021
Historique:
entrez: 27 10 2021
pubmed: 28 10 2021
medline: 30 11 2021
Statut: ppublish

Résumé

The human and economic toll of the coronavirus disease 2019 (COVID-19) pandemic and the unknowns regarding the origins of the virus, with a backdrop of enormous advances in technologies and human understanding of molecular virology, have raised global concerns about the safety of the legitimate infectious disease research enterprise. We acknowledge the safety and security risks resulting from the broad availability of tools and knowledge, tools and knowledge that can be exploited equally for good or harm. The last 2 decades have shown us that the risks are real. They have also shown us that more traditional top-down regulations alone are not the answer. We encourage government to be thoughtful and nuanced in dealing with this significant challenge and to carefully consider human factors and the important role of organizational-level leadership before simply layering an additional bureaucratic burden on the enterprise without understanding value and cost.

Identifiants

pubmed: 34700383
doi: 10.1128/mBio.02373-21
pmc: PMC8546559
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0237321

Références

Biosecur Bioterror. 2011 Sep;9(3):205-6
pubmed: 21819224

Auteurs

David R Franz (DR)

Former commander, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.

James W Le Duc (JW)

Former director of the Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH